PTPI
Petros Pharmaceuticals, Inc.0.0120
-0.0010-7.69%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
508.47KP/E (TTM)
-Basic EPS (TTM)
-29.01Dividend Yield
0%Recent Filings
8-K
8-K
Auditor change announced
Petros Pharmaceuticals dismissed CBIZ CPAs as its independent auditor on August 29, 2025, after a brief engagement starting April 5, and immediately appointed HTL International. No disagreements arose, but a material weakness in internal controls persists from prior disclosures. This switch ensures audit continuity for the fiscal year. Oversight gaps linger.
10-Q
Q2 FY2025 results
Petros Pharmaceuticals posted a $3.3M operating loss from continuing operations for Q2 FY2025 ended June 30, 2025, up 33% y/y from $1.3M amid higher professional fees and stock-based comp, while net income swung to $5.4M thanks to a $7.0M gain on subsidiary assignment and Vivus settlement. Cash burn from continuing ops hit $2.7M over six months, offset by $8.5M net from February's equity raise, leaving $7.3M in cash and $4.4M working capital—yet liquidity falls short for 12 months, flagging going concern doubts. Warrant liability gains of $10.3M (six months) masked deemed dividends slashing EPS to $(1.29) basic/diluted on 25.9M shares, with anti-dilution effects diluting common holders. Delisting to OTC in May curbs liquidity. Nasdaq woes persist.
8-K
Subsidiaries enter creditor assignment
Petros Pharmaceuticals assigned its subsidiaries' assets to a third-party fiduciary on June 16, 2025, initiating an assignment for the benefit of creditors and classifying operations as discontinued. This follows the March 31, 2025, termination of the Vivus license, ending Stendra commercialization rights and requiring inventory transfer to Vivus. Pro forma balance sheet shows stockholders' equity of $8.0 million as of March 31, 2025. Assets now under assignee control.
8-K
Nasdaq delisting suspension imminent
Petros Pharmaceuticals faces Nasdaq delisting after failing stockholders' equity, $1.00 bid price, and low bid rules, plus public interest issues from its February 19, 2025 offering. Trading suspends May 22, 2025, shifting to OTC Markets under PTPI. The company plans to appeal to the Listing Council, staying Form 25 filing but not suspension. Delisting risks reduced visibility and liquidity.
IPO
Website
Employees
Sector
Industry
CPMD
Cannapharmarx Inc.
0.00-0.00
CRON
Cronos Group Inc. Common Share
3.16+0.11
HSTI
High Sierra Technologies Inc.
1.40+0.00
PETS
PetMed Express, Inc.
3.90+1.03
PETV
PetVivo Holdings Inc.
1.16-0.03
PLSH
Panacea Life Sciences Holdings,
0.09+0.00
PNXP
Pineapple Express Cannabis Comp
0.01+0.00
PRFX
PainReform Ltd.
0.98+0.09
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18